Gonococcal Susceptibility to CephalosporinsHawaii, 2003 to 2011

Kidd, Sarah MD, MPH*; Lee, Maria V.C. MS; Maningas, Eloisa BSMT; Komeya, Alan MPH; Kunimoto, Gail BS; O’Connor, Norman MA; Katz, Alan R. MD, MPH†‡; Wasserman, Glenn M. MD, MPH; Kirkcaldy, Robert D. MD, MPH*; Whelen, A. Christian PhD†‡

Sexually Transmitted Diseases:
doi: 10.1097/01.olq.0000431357.18959.30
Note
Abstract

Abstract: Among gonococcal isolates examined at the Hawaii State Laboratory Division from 2003 to 2011, the prevalence of elevated cefixime minimum inhibitory concentrations (MICs; ≥0.064 μg/mL) and elevated cefpodoxime MICs (≥0.19 μg/mL) increased over time. In contrast, few isolates exhibited elevated ceftriaxone MICs (≥0.094 μg/mL), and the prevalence of elevated ceftriaxone MICs did not change.

In Brief

An analysis of gonococcal isolates in Hawaii found that the prevalence of elevated cefixime minimum inhibitory concentrations increased in 2003 to 2011, but prevalence of elevated ceftriaxone minimum inhibitory concentrations did not.

Author Information

From the *Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA; †Hawaii State Department of Health, Honolulu, HI; and ‡University of Hawaii-Manoa, Honolulu, HI

The authors thank Roy Ohye, former STD Program Coordinator, and Mandy Kiaha and Laurie Gorelangton, Disease Intervention Specialists, for their invaluable contributions to Hawaii’s Gonorrhea Culture Screening Program. They also thank the clinics and laboratories that refer gonococcal isolates to Hawaii’s Gonorrhea Culture Screening Program.

The authors report no conflict of interest.

Correspondence: Sarah Kidd, MD, MPH, 1600 Clifton Rd NE, MS-E02, Atlanta, GA 30333. E-mail: HGK9@cdc.gov.

Received for publication March 8, 2013, and accepted May 14, 2013.

© Copyright 2013 American Sexually Transmitted Diseases Association